DNV-3

Dose escalation Part A Main purpose: To evaluate the safety and tolerability of DNV3 combined with Teplizumab in patients with advanced/metastatic solid tumors and lymphomas, and to explore the recommended dose for subsequent combined medication. Secondary purpose: To evaluate the pharmacokinetic (PK) characteristics and immunogenicity of DNV3 combined with Teplizumab in patients with advanced/metastatic solid tumors and lymphomas, and to provide a dose basis for subsequent clinical trials. Exploratory purpose: To explore the pharmacodynamic (PD) characteristics of DNV3 combined with Teplizumab in patients with advanced/metastatic solid tumors and lymphomas; to explore the relationship between the expression of tumor infiltrating lymphocytes (TIL), PD-L1 and lymphocyte activation gene 3 (LAG-3) in tissue samples of patients with advanced/metastatic solid tumors and lymphomas and clinical efficacy. Dose expansion Part B Primary purpose: To evaluate the anti-tumor activity of DNV3 combined with Teplizumab in patients with specific tumor types in the expansion phase; Secondary purpose: To evaluate the safety, pharmacokinetic (PK) characteristics and immunogenicity of DNV3 combined with Teplizumab in patients with specific tumor types in the expansion phase. Exploratory purpose: To explore the relationship between the expression of tumor infiltrating lymphocytes (TIL), PD-L1 and lymphocyte activation gene 3 (LAG-3) and clinical efficacy in tissue samples of patients with advanced/metastatic solid tumors and lymphomas.